NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...
NHSA (prev. SMIA)
China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...
China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement
The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...
NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials
The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin”...
China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces
The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...
China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...
China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development
The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price...
NHSA Launches Service Specifications for Medical Procurement Platform
The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement...
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...
China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024
The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price...
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL)...
China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings
The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...
NHSA Completes Expert Review for National Reimbursement Drug List Updates
The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage...
NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management
The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
The EU Chamber of Commerce in China has released its bi-annual “European Business in China...